SWOT ANALYSIS OF AMGEN INC. SWOT ANALYSIS OF AMGEN INC. 4.

Running head: SWOT ANALYSIS OF AMGEN INC
SWOT ANALYSIS OF AMGEN INC
Name of the Student:
Name of the University:
Author’s Note:

1SWOT ANALYSIS OF AMGEN INC
SWOT analysis of AMGEN INC:-
Strength Weakness
 Amgen Inc. has a considerable asset base, which
delivers it with improved solvency.
 Amgen Inc. has capitalized widely in the training of
its workers that has occasioned in it, engaging a
large number of capable and inspired workers.
 Amgen Inc.’s minimum cost structure aids it makes
at a low charge and vend its products at a minimum
price, making it reasonable for its clients.
 A substantial quantity of the property that this
organization owns is borrowed rather than obtained. It
has to recompense large volumes of payment on these
totaling to its budgets (Day, 2017).
 Amgen Inc's present arrangement and culture have
occasioned in the letdown of various unions aimed at
upright integration.
 Nonexistence of legal knowledge and legal
department workers are not extremely qualified.
Opportunity Threat
 The technology originates with several paybacks
among numerous departments. Procedures can be
mechanized to decrease costs. Technology permits
better information to be collecting on clients and
recovers on marketing determinations (Kay et al.,
2014).
 The development in tourism is helpful for this
organization as it will deliver new potential clients
that it can mark in order to gain marketplace share.
 The population has been rising and is predicting to
propagate at an optimistic rate for the future years.
These are valuable for Amgen Inc as there will be a
rise in the number of potential clients that it can
mark.
 The exchange rate retains changing, and this marks
this company that has sales globally, while its dealers
are local.
 Guidelines on global trade keep changing, and this
needs amenability by businesses if they are to
function globally .
 Constant technical developments need the staff to be
qualified as the incapability to keep up with these
variations can lead to damage to industry for Amgen
Inc.

2SWOT ANALYSIS OF AMGEN INC
Porter Five Forces analysis of AMGEN INC:-
The threat of Substitutes product
Actual few alternates are existing for the merchandises that are manufacturing in the
Amgen Inc. The specific replacements that are accessible are also forming by low revenue
earning businesses. These denote that there is no upper limit on the maximum revenue that
businesses can receive in this business.
The threat of new Entry
Risks of entrance in this organization scheduling the non-strategic production sector are
little owing to the detail that constructing wafer fabs as well as purchasing devices is very
luxurious.
Bargaining Power of Supplier
The dealer of Amgen Inc scheduling the non-planning market has a little negotiating
power while that the market has the sovereignty of 3 gamers entailing of Nanya, Powerchip, and

3SWOT ANALYSIS OF AMGEN INC
ProMOS (Coelho, 2018). This business was also planning the non-strategic makers are essential
preliminary tools dealers in critical businesses with overseas gamers in altercation for modern
technical knowledge.
Degree of rivalry
The risk of replacements on the market is enormous, given the detail that the organization
participates with some most prominent organization Intel, IBM, Motor (Porter et al., 2017).
These propose that the market has an extraordinary level of competition where companies that
have style as well as progress abilities, in addition to making ability, may have the capability to
have a higher transferring power above the marketplace.
Bargaining Power of Buyer
The market is controlling by companies like Elpida, Micron, and Samsung, which better
lesser the purchasing powers of this organization. The information that these critical performers
do not permit the organization to have access to improvement suggests that they have an
advanced negotiating power comparatively.

4SWOT ANALYSIS OF AMGEN INC
References:-
Coelho, A. C. D. (2018). Amgen and Incyte: the biotechnology acquisition (Doctoral
dissertation).
Day, J. (2017). Inpatient dialysis unit project development: Redesigning acute hemodialysis care.
Nephrology Nursing Journal, 44(3), 251.
Kay, J., Chopra, A., Chandrashekara, S., Olakkengil, D. J., Bhojani, K. S., Bhatia, G., ... &
Shneyer, L. (2014). OP0012 A Phase 3, randomized, double-blind, active comparator
study of the efficacy and safety of Bow015, a biosimilar Infliximab, in patients with
active rheumatoid arthritis on stable Methotrexate doses. Annals of the Rheumatic
Diseases, 73(Suppl 2), 64-64.
Porter, J. K., Di Tanna, G. L., Villa, G., Brennan, A., Palmer, S., Lipton, R. B., ... & Sapra, S.
(2017). Parametric Modelling of Migraine Day Frequency In Migraine Prevention: A
Case Study Of Erenumab Clinical Trial Data. Value in Health, 20(9), A733.